Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial
In the late-stage trial called IKEMA, Sarclisa, when added to carfilzomib and dexamethasone, met the primary endpoint by delivering significantly prolonged progression-free survival compared to standard of care
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.